Catalyst Wire Dossier Catalyst Wire Dossier

2-HOBA (2-hydroxybenzylamine)

2-hydroxybenzylamine
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for 2-HOBA (2-hydroxybenzylamine), covering 2026-02-19 to 2026-02-19. Get the full timeline:

Most recent: Clinical Trial Update: This Study Investigates β-hydroxy-β-methylbutyrate (HMB) and 2-hydroxybenzylamine (2-HOBA), When Administered Either Individually or in Combination Contributes to an Increased Quality of Health, Specifically Improving Muscular Strength and Cognitive Functioning in Adults Over the Age of 65. [NA]

See pricing